No cases of acute overdose have been reported with COTAZYM® (pancrelipase capsules, USP). Hyperuricemia and/or hyperuricosuria have been reported in patients chronically taking high doses of COTAZYM® (pancrelipase capsules, USP). The minimum effective dose of COTAZYM® should be determined and adhered to for each patient. Large doses of delayed-release pancreatic enzyme preparations taken by patients with cystic fibrosis have been associated with fibrosing colonopathy (see PRECAUTIONS ).

COTAZYM® (pancrelipase capsules, USP) is contraindicated in those individuals who are hypersensitive to antigens of porcine origin.

Bookmark this page: